



**VGX Pharmaceuticals to present at the Second International Conference  
on Cancer Vaccines/Adjuvants/Delivery**

**Blue Bell, PA – October 8, 2007 –**

VGX Pharmaceuticals Inc. (VGX) announced today that Professor David B. Weiner of the University of Pennsylvania and Niranjan Y. Sardesai, VGX's Vice President of Product Development, are scheduled to present at the Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CCADD) at The German Cancer Research Center in Heidelberg, Germany on October 10-12. Dr. Weiner, a VGX co-founder, is a pioneer in the field of DNA vaccines and is scheduled to present "DNA Vaccination in the Immunotherapy of Cancer" as part of the Conference's Plenary Session. Dr. Sardesai will present "Enhanced Immune Responses to DNA Vaccines via Adaptive Electroporation" as part of the session on DNA Vaccines and Electroporation.

The three-day conference will focus on a variety of different approaches to cancer vaccines, including DNA based vaccination and immunotherapy, and will include international delegates from biotechnology companies, major pharmaceutical companies, academic institutions, and government labs. Over the last two decades, DNA vaccines have become a potent means of providing immune responses or protective immunity against viruses, bacteria and parasites in many species from fish to primates, including humans. Significantly, the first DNA based products in fish and dogs are on the market. A number of DNA vaccines, comprising plasmid DNA encoding proteins from pathogens, allergens, and tumors, are being evaluated as prophylactic vaccines and therapeutic treatments for infectious diseases, allergies and cancer. The use of DNA as a means of vaccination offers potential benefits in protective efficacy, cross-strain applicability, development speed and manufacturing cost compared with conventional vaccines.

Commenting on the conference proceedings, Dr. J. Joseph Kim, CEO and President of VGX said, "VGX is excited to be presenting at this conference showcasing the latest advances in cancer vaccines and immunotherapy. Our pre-clinical research studies demonstrate the broad applicability of our proprietary electroporation based CELLECTRA™ delivery platform beyond infectious diseases and into cancer."

VGX has patented and developed the CELLECTRA™ electroporation device for the delivery of DNA vaccines and therapeutics. The company's DNA-based oncology program includes: VGX-150, a DNA therapeutic, to control the growth of melanoma and other cancers; VGX-3100, a DNA vaccine targeting human papilloma virus (HPV) as a therapeutic for cervical cancer; and VGX-3200, a DNA-based therapeutic for the treatment of cancer related cachexia and anemia. Pre-clinical data from a mouse model show significant regression of established melanoma tumors after the introduction of VGX-150, using electroporation technology. Similarly, VGX has demonstrated regression of cervical cancer lesions and significant survival in an aggressive mouse model of cervical cancer when treated with the HPV vaccine compared to untreated controls. VGX-3100 and VGX-3200 are presently undergoing IND enabling pre-clinical GLP toxicology studies in combination with the CELLECTRA™ device. The company expects to file an IND for both of these products in the first quarter of 2008.

**Cautionary Factors That May Affect Future Results** - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on [www.vgxp.com](http://www.vgxp.com) as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

**About VGX Pharmaceuticals**

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at [www.vgxp.com](http://www.vgxp.com).

**Company Contact:**

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: [Rassas@vgxp.com](mailto:Rassas@vgxp.com)

[www.vgxp.com](http://www.vgxp.com)